Medical Research Council - PT20

 

PT20 was invented in the UK at the Medical Research Council (MRC)'s Human Nutrition Research laboratory in Cambridge.

Medical Research Council - PT20

< Back

PT20 is a novel ferric iron-based phosphate binder modified to create a high capacity “phosphate sponge” developed for the treatment of hyperphosphataemia which is a life-threatening complication of dialysis dependent chronic kidney disease.

Mewburn Ellis partner, Simon Kiddle, has worked closely from the start with the inventors helping the MRC to obtain broad protection for PT20.

A broad platform application delivers results

Simon recommended filing a broad platform application (WO 2008/96130) to as the class of materials have a range of different uses, with follow-up applications for the specific phosphate binding material (WO 2010/015827).

A strategy involving parallel national and international (PCT) filings, and the successful use of accelerated examination, led to early allowances in the UK and the United States.

Funding of €10.5 million

The global IP rights were exclusively licensed to Phosphate Therapeutics, a specialty pharmaceutical company in 2012.

The robust IP protection for PT20 has been important in securing a €10.5m investment from Inventages Venture Capital. A Phase 2b PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD) was completed in May 2015.

Mewburn Ellis’s advice significantly accelerated and broadened the IP protection for PT20. We are very happy to have helped the MRC fully exploit this vitally important invention.